
View larger version (28K):
[in this window]
[in a new window]
|
Fig. 4. Ey and So bind specifically to the core eye-enhancer.(A)
Sequence of two potential binding sites for So (red) and Pax6 (blue) present
in probe III. Consensus sequences are shown above. The sequence changes
introduced to disrupt protein-DNA interactions are underlined. (B)
Schematic showing the six overlapping probes (I-VI) used in EMSA. Green bars
mark the conserved sequences A1 and A2. The relative position of the So and
Pax6 sites within A1 is indicated. (C) EMSA with Ey protein. The
position of the shifted Ey-III complex is marked by an arrow. Ey shifts probe
III (lane 4) but not other probes (lanes 2,3,5,6,7). The binding of Ey to
probe III can be competed by unlabeled III DNA (lane 10) but not by unlabeled
Pax6MUT-III DNA (lane 11). Probes (I-VI), protein (Ey) and/or
competitor DNA (S,NS) added to each reaction are listed above each lane. S,
specific: non-labeled probe III DNA. NS, non-specific: non-labeled probe III
with the Pax6MUT site. Reticulocyte lysate (L) only was added in
the negative controls (lanes 1,8). The lower band (arrowhead) reflects a
non-specific shift due to the lysate. (D) EMSA with So protein
(GSTSoSixHD). The position of the shifted GSTSoSixHD-III
complex is marked by an arrow. GSTSoSixHD shifts probe III (lane 4)
but not the other probes (lanes 2,3,5,6,7). The binding of So to probe III can
be competed by unlabeled DNA with a So-binding site, but not by unlabeled
SoMUT-III DNA. Probes (I-VI), protein (GSTSoSixHD)
and/or competitor DNA (S,NS1,NS2) added to each reaction are listed above each
lane. GST was added to the negative controls (lanes 1,8). S, unlabeled
soAE oligo [So-binding site from Pauli et al.
(Pauli et al., 2005 )]; NS1,
unlabeled probe II DNA; NS2, unlabeled probe III with the SoMUT
site.
|